SCHEDULE: Aura Biosciences Files Exit Amendment to Schedule 13D

Aura Biosciences, Inc. has filed an exit amendment to its Schedule 13D, reporting the repurchase of 6,922,870 shares of common stock by the issuer from Matrix Fund.

Summary

• This filing is an amendment to a previous Schedule 13D, specifically Amendment No. 4, and serves as a final "exit filing" for the reporting persons.
• The primary event detailed is the repurchase of 6,922,870 shares of Aura Biosciences, Inc. common stock by the issuer from Matrix Fund.
• This repurchase occurred on May 7, 2026, at a price of $5.64 per share.
• The transaction was contingent upon the closing of a separate equity offering by Aura Biosciences and other conditions.
• The reporting persons, Matrix Capital Management Company LP and David E. Goel, have reported 0% beneficial ownership of the company's common stock after this transaction.
• No other transactions in the company's common stock were effected by the reporting persons in the sixty days prior to this filing, other than the described repurchase.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the exit of a significant investor and the implication of a potentially distressed equity offering, despite the share repurchase.

Positives

• The repurchase of shares by the issuer could be viewed positively as it reduces outstanding shares, potentially increasing earnings per share for remaining shareholders.
• The transaction was completed, indicating the fulfillment of agreed-upon conditions.

Negatives

• The reporting persons have exited their position, indicating a lack of further investment interest at this time.
• The repurchase price of $5.64 per share may be lower than the price at which Matrix Fund originally acquired the shares, suggesting a potential loss on investment for them.

Risks

• The filing mentions the repurchase was contingent on the closing of a separate equity offering by the Issuer, implying potential risks associated with that offering's success.
• The exit of a significant investor like Matrix Capital Management Company LP could be perceived negatively by the market, potentially impacting investor confidence.

Future Outlook

The filing itself is an exit filing, indicating the reporting persons are no longer significant beneficial owners. Future outlook for Aura Biosciences would depend on factors not detailed in this specific amendment, such as the success of their separate equity offering and ongoing business operations.

Management Comments

• "This Amendment No. 4 is the final amendment to the Schedule 13D and constitutes an 'exit filing' for the Reporting Persons."
• "On April 30, 2026, the Matrix Fund agreed to sell and the Issuer agreed to repurchase 6,922,870 shares of Common Stock from the Matrix Fund at a price of $5.64 per share, contingent upon the closing of a separate equity offering by the Issuer and certain other conditions (the 'Repurchase')."
• "The Repurchase closed on May 7, 2026."
• "Except for the Repurchase, no transactions in the shares of Common Stock have been effected by the Reporting Persons during the past sixty (60) days."

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes in public companies. An 'exit filing' like this one, detailing a substantial share repurchase, often signals a shift in investor strategy or a conclusion to a prior investment thesis. The contingent nature of the repurchase on an equity offering highlights the company's ongoing need for capital and the interconnectedness of corporate finance activities.

Related Party Transactions

• The repurchase of 6,922,870 shares of Common Stock by Aura Biosciences, Inc. from Matrix Fund at $5.64 per share on May 7, 2026, is a related party transaction as Matrix Fund is a reporting person.

Stakeholder Impact

• Shareholders: The repurchase reduces the number of outstanding shares, which could be positive for remaining shareholders if the company's value is maintained or increases. However, the exit of a significant investor might signal concerns about future performance.
• Creditors: The company's need to conduct an equity offering to fund the repurchase could impact its debt-to-equity ratio and financial leverage.
• Management: The company's management will need to successfully execute the equity offering and demonstrate future growth without the support of Matrix Capital Management.

Next Steps

• Aura Biosciences, Inc. is expected to complete its separate equity offering.
• The company will continue its business operations without the significant involvement of Matrix Capital Management Company LP.

Key Dates

Recommendation

The filing indicates a significant investor's exit and a contingent equity raise, creating uncertainty. While the share repurchase might offer some support, the lack of further positive catalysts and the potential implications of the equity offering warrant a cautious 'hold' stance until more information on the company's operational and financial trajectory is available.

Keywords

Schedule 13D, Aura Biosciences, Matrix Capital Management, Share Repurchase, Exit Filing, SEC Filing, Common Stock, Beneficial Ownership